EpiPen price increases
how regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY)
How regulatory barriers inhibit pharmaceutical competition
United States
Congress.
Senate.
Committee on Health, Education, Labor, and Pensions.
Subcommittee on Children and Families,
creator
text
bibliography
dcu
2018
monographic
eng
iii, 43 pages : illustrations ; 24 cm.
Shipping list no.: 2019-0162-M.
GPO Cataloging Record Distribution Program (CRDP).
Includes bibliographical references.
Microfiche. [Washington, D.C.] : U.S. Government Printing Office, [2018] 1 microfiche : negative.
n-us---
Prescription pricing
United States
Drugs
Law and legislation
United States
Pharmaceutical industry
United States
Competition
United States
Drug delivery devices
Prices
United States
Competition
Drugs
Law and legislation
Pharmaceutical industry
Prescription pricing
United States
KF26 .L2733 2016
Y 4.L 11/4:S.HRG.114-805
Y 4.L 11/4:S.HRG.114-805
EpiPen price increases
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families.
(DLC) 2018439951
(OCoLC)1078409593
EpiPen price increases
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families.
(OCoLC)1078951640
S. hrg. ; 114-805
United States.
Congress.
Senate.
PUCPR
200424
20200512084940.0
on1151883907
eng